In this episode of Topical Conversations, Dr. Michael Cameron and Dr. Graham Litchman explore the pathophysiology of type 2 inflammation in dermatologic diseases and discuss how evolving treatment options are reshaping clinical practice. From atopic dermatitis (AD) and prurigo nodularis (PN) to chronic spontaneous urticaria (CSU), they break down the mechanisms of disease, targeted therapies, and emerging treatment strategies that are changing the way dermatologists approach inflammatory skin conditions.
Understanding type 2 inflammation across dermatologic diseases
Since the approval of dupilumab in 2017, research into type 2 inflammation has expanded dramatically. Dr. Litchman highlights how this shared inflammatory pathway connects conditions such as asthma, allergic rhinitis, AD, PN, and CSU, allowing dermatologists to educate patients on the systemic nature of their disease.
Dr. Cameron emphasizes the complex immune dysregulation in type 2 diseases, particularly the cross-talk between inflammatory cells. He explains that IL-4 and IL-13, key drivers of AD and PN, are present not only on inflammatory cells but also on sensory nerves, contributing to chronic itch. Targeted therapies like dupilumab, tralokinumab, lebrikizumab, and nemolizumab work by interrupting these signaling pathways, leading to symptom relief.
Emerging therapies and novel mechanisms of action
The discussion shifts to next-generation treatments that go beyond blocking cytokine communication to directly targeting inflammatory cells. Dr. Litchman shares excitement about the potential of Bruton’s tyrosine kinase (BTK) inhibitors that prevent mast cell activation and degranulation; JAK1 inhibitors that have the potential to expand options for systemic inflammatory control; monoclonal antibodies that look to directly inhibit IL-5, IL-13, and eosinophils, offering new avenues for treatment; and OX40 ligand inhibitors, that work by eliminating pathogenic T cells rather than just blocking their signals.
Dr. Cameron highlights key priorities in drug development, including longer dosing intervals (every 3 months), higher efficacy (bispecific and trispecific antibodies), and more oral treatment options.
The role of dermatologists in managing CSU and PN
CSU is often referred out, but both doctors agree that dermatologists should reclaim these patients. Dr. Cameron points out that many patients with CSU patients are also atopic, reinforcing that dermatologists are well-equipped to manage their care. With BTK inhibitors and anti-c-Kit therapies emerging, now is the time to bring CSU management back into dermatology practices.
For PN, the approval of dupilumab and nemolizumab has been a breakthrough. Previously neglected due to a lack of therapeutic options, patients with PN now have access to effective, targeted treatments. Dr. Cameron emphasizes that many patients with PN also have coexisting atopic conditions, making these therapies beneficial beyond PN alone.
Key takeaways:
In this 45-minute symposium, expert faculty cover the latest updates for JAK inhibitors, including head-to-head efficacy and safety data for JAK inhibitors and biologics, and share clinical pearls for using JAK inhibitors in dermatology practice for atopic dermatitis."I can say that in my clinic, I am reaching for those high bars. You have toput yourself in the position of the patient or imagine that patient is your family member. Would you want mediocre treatment for them or average treatment or moderate treatment? You’d want them to get the best possible treatment. In my practice I’m now counseling patients 'yes we want clear skin. Yes, we want minimal itch. Yes we want your skin pain gone and for you to sleep better.'”- David Cotter, MD, PhDFC25: Charting the Course to Higher Targets With JAK Inhibition in Atopic Dermatitis: An Online ActivityThis activity is supported by an educational grant from AbbVie.
Don’t miss this Satellite Symposium from the 2025 Fall Clinical Dermatology Conference®, as Dr. Alexandra Golant, Dr. Mona Shahriari, and Dr. G. Michael Lewitt discuss IL-13 targeting biologics in the treatment of atopic dermatitis as well as strategies for optimizing their use.“To me, coming into an exam room in 2025, when we have so many different treatment options for these patients, it's a unique opportunity to use what we know about the data of these therapeutics and walk patients though their options and how to understand their disease state, and how to best choose the therapy that feels right for them.” – Alexandra Golant, MD FC25: Illuminate the Role of IL-13 Inhibitors for the Management of Atopic DermatitisThis activity is supported by an educational grant from Lilly.
“Of course we’re always starting with our basics: we’re using our gentle cleansers, our moisturization, our avoidance of known allergens or triggers, and then we're doing our topicals. But it can be very difficult if you have heavy stuff on your face or you’re required to put it on over and over. It can be really tough. So this paves the way really nicely to say it is time to move up, it is time to think about the next level, and typically the next step up is going to be a biologic agent.” - Peter Lio, MDA ‘HowTo’ activity delivers a short burst of engaging and compact content for learners to study at their own convenience. This microlearning activity is intended to provide practical insights from two experts on ‘HowTo’ improve care in head and neck atopic dermatitis in 10 minutes.This activity is supported by an educational grant from LEO Pharma.
This 30-minute symposium from the 2025 Pediatrics360 Virtual Conference takes a closer look at biologic therapies that can address the immune pathophysiology, associated comorbidities, and progression of moderate-to-severe atopic dermatitis in pediatric patients.“A lot of them (children with atopic dermatitis) do have tactile sensitivities and don’t like the way any creams, ointments, anything, feel on their skin. Thinking about a shot, even though it hurts, doing a shot once or twice a month can actually often be so much easier than having the parents have to argue with the kid two to three times a day to get the topicals on. So, I actually think of injections very quickly for patients with tactile sensitivities.” – Dr. Elizabeth SwansonPEDS25: Controlling the Wolf in Sheep’s Clothing: Managing Pediatric Atopic Dermatitis with Biologic Therapies: An Online ActivityThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals, Inc.